259 related articles for article (PubMed ID: 10961860)
1. Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?
Reuter CW; Morgan MA; Bergmann L
Blood; 2000 Sep; 96(5):1655-69. PubMed ID: 10961860
[TBL] [Abstract][Full Text] [Related]
2. Ras processing as a therapeutic target in hematologic malignancies.
Le DT; Shannon KM
Curr Opin Hematol; 2002 Jul; 9(4):308-15. PubMed ID: 12042705
[TBL] [Abstract][Full Text] [Related]
3. Ras family signaling: therapeutic targeting.
Cox AD; Der CJ
Cancer Biol Ther; 2002; 1(6):599-606. PubMed ID: 12642680
[TBL] [Abstract][Full Text] [Related]
4. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development.
Rowinsky EK; Windle JJ; Von Hoff DD
J Clin Oncol; 1999 Nov; 17(11):3631-52. PubMed ID: 10550163
[TBL] [Abstract][Full Text] [Related]
5. Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy.
Lancet JE; Karp JE
Blood; 2003 Dec; 102(12):3880-9. PubMed ID: 12920034
[TBL] [Abstract][Full Text] [Related]
6. Induction of N-myc in neuroblastoma by autocrine IGF-II depends on farnesylated Ras. Application of farnesyltransferase inhibitors.
Wittrock J; Schweizer P; Girgert R
Anticancer Res; 2002; 22(6C):4205-9. PubMed ID: 12553057
[TBL] [Abstract][Full Text] [Related]
7. [Ras signaling pathway as a target for farnesyltransferase inhibitors--a new, promising prospects in the treatment for malignant disorders].
Helbig G; HoĊowiecki J
Wiad Lek; 2004; 57(9-10):462-7. PubMed ID: 15765763
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of the ras oncogene as therapeutic targets.
Ghobrial IM; Adjei AA
Hematol Oncol Clin North Am; 2002 Oct; 16(5):1065-88. PubMed ID: 12512383
[TBL] [Abstract][Full Text] [Related]
9. Protein farnesyltransferase inhibitors.
Ayral-Kaloustian S; Salaski EJ
Curr Med Chem; 2002 May; 9(10):1003-32. PubMed ID: 12733981
[TBL] [Abstract][Full Text] [Related]
10. Role of farnesyltransferase inhibitors in hematologic malignancies.
Santos ES; Rosenblatt JD; Goodman M
Expert Rev Anticancer Ther; 2004 Oct; 4(5):843-56. PubMed ID: 15485318
[TBL] [Abstract][Full Text] [Related]
11. Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action.
Jabbour E; Kantarjian H; Cortes J
Leuk Lymphoma; 2004 Nov; 45(11):2187-95. PubMed ID: 15512806
[TBL] [Abstract][Full Text] [Related]
12. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
Sebti SM; Hamilton AD
Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
[TBL] [Abstract][Full Text] [Related]
13. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics.
Gibbs JB; Oliff A
Annu Rev Pharmacol Toxicol; 1997; 37():143-66. PubMed ID: 9131250
[TBL] [Abstract][Full Text] [Related]
14. Ras farnesyltransferase inhibitors suppress the phenotype resulting from an activated ras mutation in Caenorhabditis elegans.
Hara M; Han M
Proc Natl Acad Sci U S A; 1995 Apr; 92(8):3333-7. PubMed ID: 7536929
[TBL] [Abstract][Full Text] [Related]
15. Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice.
Liu M; Bryant MS; Chen J; Lee S; Yaremko B; Li Z; Dell J; Lipari P; Malkowski M; Prioli N; Rossman RR; Korfmacher WA; Nomeir AA; Lin CC; Mallams AK; Doll RJ; Catino JJ; Girijavallabhan VM; Kirschmeier P; Bishop WR
Cancer Chemother Pharmacol; 1999; 43(1):50-8. PubMed ID: 9923541
[TBL] [Abstract][Full Text] [Related]
16. Pre-clinical development of farnesyltransferase inhibitors.
Lobell RB; Kohl NE
Cancer Metastasis Rev; 1998 Jun; 17(2):203-10. PubMed ID: 9770117
[TBL] [Abstract][Full Text] [Related]
17. The development of protein farnesyltransferase inhibitors as signaling-based anticancer agents.
Ohkanda J; Blaskovich MA; Sebti SM; Hamilton AD
Prog Cell Cycle Res; 2003; 5():211-7. PubMed ID: 14593715
[TBL] [Abstract][Full Text] [Related]
18. Farnesyltransferase inhibitors. Preclinical development.
Kohl NE
Ann N Y Acad Sci; 1999; 886():91-102. PubMed ID: 10667207
[TBL] [Abstract][Full Text] [Related]
19. Farnesyltransferase inhibitors.
Hahn SM; Bernhard E; McKenna WG
Semin Oncol; 2001 Oct; 28(5 Suppl 16):86-93. PubMed ID: 11706400
[TBL] [Abstract][Full Text] [Related]
20. Ras farnesyltransferase inhibition: a novel and safe approach for cancer chemotherapy.
Nammi S; Lodagala DS
Acta Pharmacol Sin; 2000 May; 21(5):396-404. PubMed ID: 11324435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]